PT  - JOURNAL ARTICLE
AU  - Beall, Douglas P.
AU  - Wilson, Gregory L.
AU  - Bishop, Randolph
AU  - Tally, William
TI  - VAST Clinical Trial: Safely Supplementing Tissue Lost to Degenerative Disc Disease
AID  - 10.14444/7033
DP  - 2020 Apr 01
TA  - International Journal of Spine Surgery
PG  - 7033
4099  - https://www.ijssurgery.com/content/early/2020/04/13/7033.short
4100  - https://www.ijssurgery.com/content/early/2020/04/13/7033.full
AB  - Background The function of the intervertebral disc is structural. Loss of tissue alters biomechanics, leads to subsequent disc degeneration, and is attributable to discogenic pain. A viable structural allograft was delivered into degenerate discs to determine whether intervention could safely stabilize anatomy, reduce pain, and improve function.Methods Following institutional review board approval and patient consent, subjects were randomized to receive allograft or saline at either 1 or 2 levels or continue nonsurgical management (NSM). Data were collected at baseline, 3, 6, and 12 months. Back pain with a visual analog scale (VAS) and disability by the Oswestry Disability Index (ODI) were assessed, as were adverse events. This trial is registered on http://www.clinicaltrials.gov (NCT03709901).Results At 6 and 12 months, the VAS improved from 54.81, 55.25, and 62.255 in the allograft, saline, and NSM subjects, respectively, to 16.0 and 41.0 in the allograft and saline groups at 6 months, and 12.27 and 19.67, respectively, at 12 months. All subjects in the NSM cohort crossed over to allograft treatment. At 6 and 12 months, ODI improved from 53.73, 49.25, and 55.75 in the allograft, saline, and NSM subjects, respectively, to 18.47 and 28.75 in the allograft and saline groups 1 and 2 at 6 months, and 15.67 and 9.33, respectively, at 12 months. At 3 months the ODI of the NSM group was 62.75 and subjects reached 19.0 and 11.0 at 6 and 12 months, respectively. Adverse events were transient and resolved in all cohorts.Conclusions This study is supported by data demonstrating that improved pain and function at 12 months can be attained with a supplemental viable disc matrix. Subjects receiving the VIA Disc Matrix achieved improvements that were durable at 12 months.Level of Evidence 1.Clinical Relevance Initial assessments indicate that a 1-level or 2-level treatment offers a reliable intervention that is safe and beneficial.